236 related articles for article (PubMed ID: 7626598)
1. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.
Gulnik SV; Suvorov LI; Liu B; Yu B; Anderson B; Mitsuya H; Erickson JW
Biochemistry; 1995 Jul; 34(29):9282-7. PubMed ID: 7626598
[TBL] [Abstract][Full Text] [Related]
2. Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new derivatives.
Nair AC; Bonin I; Tossi A; Wels WJ; Miertus S
J Mol Graph Model; 2002 Dec; 21(3):171-9. PubMed ID: 12463635
[TBL] [Abstract][Full Text] [Related]
3. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
Pazhanisamy S; Stuver CM; Cullinan AB; Margolin N; Rao BG; Livingston DJ
J Biol Chem; 1996 Jul; 271(30):17979-85. PubMed ID: 8663409
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
[TBL] [Abstract][Full Text] [Related]
5. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
[TBL] [Abstract][Full Text] [Related]
6. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
7. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
Todd MJ; Luque I; Velázquez-Campoy A; Freire E
Biochemistry; 2000 Oct; 39(39):11876-83. PubMed ID: 11009599
[TBL] [Abstract][Full Text] [Related]
8. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanics analysis of drug-resistant mutants of HIV protease.
Weber IT; Harrison RW
Protein Eng; 1999 Jun; 12(6):469-74. PubMed ID: 10388843
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
11. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
Velazquez-Campoy A; Kiso Y; Freire E
Arch Biochem Biophys; 2001 Jun; 390(2):169-75. PubMed ID: 11396919
[TBL] [Abstract][Full Text] [Related]
12. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.
Chen Z; Li Y; Schock HB; Hall D; Chen E; Kuo LC
J Biol Chem; 1995 Sep; 270(37):21433-6. PubMed ID: 7665551
[TBL] [Abstract][Full Text] [Related]
14. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
[TBL] [Abstract][Full Text] [Related]
16. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
[TBL] [Abstract][Full Text] [Related]
17. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF
Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574
[TBL] [Abstract][Full Text] [Related]
18. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.
Mahalingam B; Louis JM; Reed CC; Adomat JM; Krouse J; Wang YF; Harrison RW; Weber IT
Eur J Biochem; 1999 Jul; 263(1):238-45. PubMed ID: 10429209
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Hong L; Zhang XC; Hartsuck JA; Tang J
Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
[TBL] [Abstract][Full Text] [Related]
20. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
